Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

13-09-2022 | ESMO 2022 | Conference coverage | Video

COSMIC-313 points to first-line triplet option for advanced RCC

Toni Choueiri tells us about the COSMIC-313 trial evaluating the addition of cabozantinib to nivolumab plus ipilimumab in intermediate- or poor-risk patients with treatment-naïve, advanced renal cell carcinoma (2:53).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

18-02-2021 | ASCO GU 2021 | Conference coverage | Video

Cabozantinib–nivolumab and ipilimumab combinations show potential for GU cancers

17-06-2022 | Renal cell carcinoma | News

CheckMate 9ER update confirms first-line nivolumab plus cabozantinib benefits for advanced RCC

16-02-2021 | ASCO GU 2021 | Conference coverage | News

Lenvatinib plus pembrolizumab achieve CLEAR survival advantage for clear cell RCC

09-06-2020 | ASCO 2020 | News

KEYNOTE-426 update ‘continues to support’ pembrolizumab plus axitinib

  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits